Navin Fluorine International Ltd Q4 FY2022 Concall Summary

Key Takeaways

• Record year, margin pinch: FY22 revenue grew 25% in Specialty Chemicals and delivered record sales across CRAMS and Inorganic Fluorides, but Q4 EBITDA margin compressed to 24% as energy costs spiked and employee costs rose ahead of new plant start-ups.
• New molecule anchors the growth story: A Rs. 540 crore CAPEX for a fluoro specialty molecule with ~Rs. 600 crore peak revenue potential was announced, backed by a multi-year supply agreement and a proprietary, environment-friendly technology that management calls more profitable than all prior projects.
• FY23 is the investment year, FY24 the payoff: Three major plants will be commissioned through FY23, pushing employee costs higher before sales ramp; management expects a significant margin uptick from FY24 as these assets annualize and higher-margin contracts kick in.
• CRAMS order book signals a breakout: After a lumpy year, the CRAMS pipeline is described as "extremely strong" for calendar 2023, with multiple campaigns likely and some manufacturing needing to start as early as Q3 FY23.
• What to watch next quarter: Whether the HPP plant begins commercial production on schedule this month, any further clarity on the refrigerant opportunity that currently fails internal filters, and the pace of energy cost pass-through that will determine near-term margin recovery.

The New Fluoro Specialty Molecule: Platform, Partner, Profit

• Project structure: Navin Fluorine Advanced Sciences will invest Rs. 540 crore in a Dahej facility to manufacture a fluoro specialty molecule, with peak revenue potential of ~Rs. 600 crore. The base load is secured through a multi-year supply agreement with a multinational, and the plant is expected ready by December 2023 with supplies commencing immediately.
• Volume strategy with upside optionality: 50% of volume is locked under a cost-plus contract with the technology partner; the remaining 50% can be sold to other customers or used internally for two downstream molecules, one already mapped in the MPP project. Management conservatively modelled the full Rs. 600 crore revenue at the locked-in price but believes the open 50% carries "significant upside potential" given current market conditions.
• Proprietary technology as a moat: Navin will be the only manufacturer using this particular technology, which management describes as "far superior and completely environment-friendly" compared to existing processes. Some competing plants using older methods have received closure notices, tightening supply.
• Platform, not just a product: The molecule is a critical fluorine building block used across multiple value chains to manufacture downstream derivatives. Management sees the indirect impact of the project as "much bigger" than the Rs. 600 crore standalone revenue, with the technology opening doors to other opportunities outside this specific molecule.
• Partnership depth signals ambition: The technology partner relationship extends to the CEO level, with other important projects already underway between the two companies. Management stated there is "intent and opportunities identified to grow this relationship to \$100 million plus."

Welling: "This is a critical fluorine building block, which is basically going to be used in a number of value chains to manufacture a number of downstream derivatives."

Margin Bridge: What Compressed, What Recovers

• Energy cost spike hit Q4: A sharp rise in energy costs could not be passed through immediately due to existing contract terms, compressing gross margins. Management expects to pass these costs on in coming months and sees the pressure resolving "in a quarter or two" absent new surprises.
• Employee cost loaded ahead of revenue: Higher employee costs from new hiring for three upcoming plants, retention-linked variable pay, and talent availability pressures pushed up the cost ratio. These plants will commission through FY23, so the ratio stays elevated until sales annualize from FY24 onward, when management expects a "significant drop."
• Cost pass-through being tightened: For all announced projects except MPP, contracts are on a cost pass-through basis. Navin is negotiating to shorten the adjustment period from one year to six months or quarterly, including catch-up for prior-period overruns, with management expecting "net-net, 100% pass-through."
• New projects structurally higher-margin: Almost all new projects were conceived at higher gross margins than the base business. Combined with the employee cost ratio dropping from FY24, management expects a "significant margin uptick" starting that year. The new fluoro molecule project is likely to be more profitable than all previously announced projects, with an IRR "on the much higher side."
• Pharma margin drag had a specific cause: A significant drop in pharma business came from one molecule supplied into the ARV segment. Navin quickly developed a replacement opportunity, but the substitute carried slightly lower gross margins, creating a mix headwind. Management internally assumes the original demand may not return soon and has a Plan B in place.

Welling: "We believe that the rest of the 50% we could have significant upside potential given what is going on in the market right now. But just to be conservative, we've actually done the financials, assuming that the price for the rest of the 50% will also be the same."

CRAMS: A Lumpier Business Primed for a Strong 2023

• Record FY22 despite lumpiness: CRAMS delivered record annual sales in FY22, but management cautioned the business tends to be "extremely lumpy." The current pipeline, however, points to an "extremely strong order book for calendar year 2023" with many campaigns likely.
• Three structural growth drivers: Repeat business from strategic key accounts, molecules that have been in development for some time now seeing good market growth, and a pipeline of new customers acquired at the front end of their product development cycles all support mid-to-long term traction.
• Near-term manufacturing pull: Some molecules for 2023 campaigns need manufacturing to start from Q3 FY23 (Q4 calendar 2022), and management is trying to pull some into H1. Three more molecules are progressing "extremely well" in the CRAMS pipeline, following one that was commercialized about two years back.
• CGMP4 planning underway: Based on customer feedback for 2023 campaigns, Navin has already started working on a CGMP4 plan, though no internal deadline has been set for Board presentation.

Legacy Business Performance

The Refrigerant Question and What Lies Beyond

• Refrigerant opportunity stuck at the gate: Navin is working on a refrigerant opportunity and has completed basic engineering, so the project could be executed within the stipulated time if approved. However, it currently fails internal financial filters, and management is "trying to slice and dice it in multiple ways to see if we can actually make it work."
• Fluoropolymers and newer chemistries still incubating: Some new product development activities have moved to the piloting stage with customer discussions ongoing, but management called it "too early to comment" and will not discuss until sales become material.
• Piramal JV evaluating one opportunity: The hexafluoroacetone platform through the Piramal joint venture is currently assessing one specific opportunity.
• New segments from FY25: Management hopes to start seeing material contribution from new emerging segments from FY25 onward.
• Balance sheet capacity exists: For new opportunities, management does not see balance sheet constraints, with a commitment to keep the debt-equity ratio below 1. The entire ~Rs. 1,100 crore of CWIP plus Rs. 300 crore of cash payout in FY23 will be capitalized in the current financial year.

Welling: "Currently, it is not meeting our internal filters. So, we're trying to currently slice and dice it in multiple ways to see if we can actually make it work. But given our internal financial metrics, it's not meeting some of those critical important requirements."

People and the Start-Up Cost Cycle

• Talent costs rose on competition and retention: Higher employee costs in Q4 came from new hiring for three upcoming plants, higher variable pay, and retention measures driven by talent availability issues. Management noted that for the right talent, "just this opportunity of getting to work on some of these exciting opportunities helps them continue to look forward to coming to work on a day-to-day basis."
• Start-up costs precede revenue: Plant start-up costs are being brought on ahead of actual commissioning, making FY23 "difficult to predict." Once all three projects have an annualized impact from FY24, employee cost as a percentage of sales will dip significantly as sales grow faster than employee cost.
• Working capital expected stable: The working capital cycle for new projects is expected to remain around the same level, as many commodity inputs cannot be stored long and are bought on a spot basis.

Welling: "For the right talent, just this opportunity of getting to work on some of these exciting opportunities helps them continue to look forward to coming to work on a day-to-day basis."

Guidance & Commitments

Key Metrics